Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could steroids ease swallowing woes in rare esophagus condition?

NCT ID NCT06588348

Symptom relief Sponsor: Baylor Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether corticosteroids can improve swallowing in people with a rare esophagus disorder called EGJOO, where food gets stuck. Researchers suspect an allergy may cause the problem. Twelve adults with swallowing difficulties or chest pain will receive the medication to see if it helps their esophagus muscles work better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patients age 18 years or older with the following clinical and diagnostic criteria will be eligible for study inclusion: * EGJOO manometric diagnosis based on CC v4.0 criteria * Primary symptom of dysphagia and/or non-cardiac chest pain * Additional objective evidence of obstruction on Timed Barium Esophagram and/or EndoFLIP * The treating physician has determined that invasive therapy (botulinum toxin injection, pneumatic dilation, POEM, or Heller myotomy) is indicated. Exclusion Criteria: * History of prior foregut surgery * History of esophageal botulinum toxin injection within 6 months of study enrollment * Presence of hiatal hernia \> 2 centimeters * Presence of esophageal mass * Obstructing esophageal stricture or ring on endoscopy * Reflux esophagitis (LA Grades B-D) * Subjects on current immunosuppression or immune modulating therapy * Chronic opioid use * Previously diagnosed extrinsic compression of the gastroesophageal junction * Concomitant Eosinophilic Esophagitis with uncontrolled mucosal disease who have not tried at least one standard therapy * Contraindication to the use of oral corticosteroids * History and/or current diagnosis of Diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophagogastric junction outflow obstruction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophagogastric junction outflow obstruction

Contacts and locations

Locations

  • Baylor University Medical Center

    Dallas, Texas, 75246, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.